Research

Scientific Articles

Find my articles via my ORCID 0000-0003-4449-6952 or on Google Scholar

Suter, R.K., …, Kaeppeli, S., …, Ayad, N. (2026). Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations. Nature Communications, 17 (99). https://doi.org/10.1038/s41467-025-67783-5

Jermakowicz, A., …, Kaeppeli, S., …, Ayad, N. (2024). Rapid resistance to BET inhibitors is mediated by FGFR1 in glioblastoma. Scientific Reports, 14 (1), 9284. https://doi.org/10.1038/s41598-024-60031-8

Roy, S., …, Kaeppeli, S., …, Gasser, G. (2021). Synthesis and biological evaluation of metallocene-tethered peptidyl inhibitors of CDC25. Organometallics, 40 (15): 2716–2723. doi.org/10.1021/acs.organomet.1c00345

Kaeppeli, S., …, Béhé, M. (2019). Exendin-4 derivatives with an albumin-binding moiety show decreased renal retention and improved GLP-1 receptor targeting. Molecular Pharmaceutics, 16 (9), 3760-3769. doi:10.1021/acs.molpharmaceut.9b00271

Kaeppeli, S., …, Béhé, M. (2019). Comparison of Desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4. EJNMMI Radiopharmacy and Chemistry, 4 (1): 9. doi:10.1186/s41181-019-0060-9

Kabakci, Z.*, Käppeli, S.*, Cantù, C.*, … Ferrari, S. (2019). Pharmacophore-guided discovery of CDC25 inhibitors causing cell cycle arrest and tumor regression. Scientific reports, 9 (1): 1335. doi:10.1038/s41598-019-38579-7

Upcoming Scientific Articles

Suter, R., …, Kaeppeli, S., …, Ayad, N. (2024). Drug and Single-Cell Gene Expression Integration Identifies Sensitive and Resistant Glioblastoma Cell Populations (under revision: Nature Communications).

Presentations

2023

Georgetown University Postdoctoral Research Symposium, April 27, Washington DC, USA
“In silico drug discovery reveals novel therapy for glioblastoma combining casein kinase 2 inhibitor CX-4945 and exportin-1 inhibitor Selinexor”

2022

Society for NeuroOncology Annual Scientific Meeting, November 18, Tampa FL, USA
“In silico drug discovery reveals subtype-specific combination therapies with casein kinase 2 inhibitor CX-4945 in glioblastoma”

2019

Propulsion Academy Final Project Meetup, July 31, Zurich, Switzerland
“PhenoCAT: (Un)supervised Classification of Microscopy Images with Deep Learning”

2018

IPW Doktorandentag, February 14, Zurich, Switzerland
“Targeting the GLP-1 receptor on pancreatic β-cells: signaling and radiopharmaceutical applications”
Honor: Anton-Lehmann-Fonds Prize for best talk

2017

BetaCure 4th General Assembly Meeting, May 30 – June 1, Turku, Finland (2017)
“WP2: Optimization and characterization of tracers”

2016

24. Jahrestagung der Arbeitsgemeinschaft Radiochemie und Radiopharmazie (AGRR), September 29 – October 1, Morschach, Switzerland
“Exendin-4 derivatives with albumin-binding moieties show favorable pharmacokinetics”

BetaCure 3rd General Assembly Meeting, May 8-10, Rüdesheim am Rhein, Germany
“WP2: GLP-1R targeting – Update on albumin binders”

Posters

2018

3rd TERACHEM Conference, September 26 – 29, Bressanone, Italy
“Targeting the GLP-1 receptor on pancreatic β-cells: Signaling and radiopharmaceutical application”

275 Jahr-Jubiläum der Zürcher Apotheken, June 22, Zurich, Switzerland
“GLP-1 receptor: From GPCR signaling to nuclear imaging”

2017

1st Zurich GPCR Day, October 25, Villigen-PSI, Switzerland
“GLP-1R as an example for GPR targeting in nuclear medicine”

13. Charles Rodolphe Brupbacher Symposium, February 1 – 3, Zurich, Switzerland
“Pre-clinical evaluation of novel exendin-4 derivatives for non-invasive insulinoma diagnosis”

2016

Cancer Biology Graduate School retreat, March 29-31, Davos, Switzerland
“Evaluation of new improved radiolabeled exendin-4 derivatives for β-cell targeting”